Using advanced imaging and blood tests to monitor melanoma patients at high risk for recurrence
Whole-body Diffusion-weighted Magnetic Resonance Imaging and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence Following Surgery or Systemic Therapy
This study is testing if advanced imaging and blood tests can help doctors better monitor melanoma patients at high risk for their cancer coming back after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitair Ziekenhuis Brussel Academic / other |
| Drugs / interventions | Ipilimumab, chemotherapy, immunotherapy, radiation |
| Locations | 2 sites (Jette, Brabant and 1 other locations) |
| Trial ID | NCT02907827 on ClinicalTrials.gov |
What this trial studies
This study focuses on patients with locally advanced melanoma who are at high risk for recurrence after surgical treatment. It employs whole-body diffusion-weighted magnetic resonance imaging (DW-MRI) and circulating free DNA (cfDNA) analysis to enhance surveillance and early detection of melanoma recurrence. The innovative approach aims to establish effective monitoring methods for patients who have undergone treatment and are in remission. By combining advanced imaging techniques with blood analysis, the study seeks to improve patient outcomes through timely intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with histologically confirmed malignant melanoma who are in complete remission and at high risk for recurrence.
Not a fit: Patients with contraindications for MRI or those who are not in remission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier detection of melanoma recurrence, potentially improving survival rates for high-risk patients.
How similar studies have performed: Other studies have shown promise in using advanced imaging and cfDNA analysis for cancer surveillance, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed malignant melanoma; * AJCC Stage III: No evidence of disease on most recent CT or PET-CT imaging * Stage IV: Complete remission for more than 3 years, confirmed by most recent CT or PET-CT imaging Exclusion Criteria: * Contra-indication for MRI: pacemaker, metallic foreign body in eye, recent operation with prosthetic material (\< 6weken) * Claustrophobia * Metallic devices implanted such as hip prostheses, since this can alter the imaging quality
Where this trial is running
Jette, Brabant and 1 other locations
- UZ Brussel — Jette, Brabant, Belgium (Recruiting)
- UZ Brussel — Brussels, Belgium (Recruiting)
Study contacts
- Principal investigator: Bart Neyns, Md Phd — Universitair Ziekenhuis Brussel
- Study coordinator: Bart Neyns, MD Phd
- Email: bart.neyns@uzbrussel.be
- Phone: 02 477 60 40
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.